These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 8570022)

  • 21. Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies.
    Kornhuber J; Parsons CG; Hartmann S; Retz W; Kamolz S; Thome J; Riederer P
    J Neural Transm Gen Sect; 1995; 102(3):237-46. PubMed ID: 8788072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain.
    Medvedev IO; Malyshkin AA; Belozertseva IV; Sukhotina IA; Sevostianova NY; Aliev K; Zvartau EE; Parsons CG; Danysz W; Bespalov AY
    Neuropharmacology; 2004 Aug; 47(2):175-83. PubMed ID: 15223296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity.
    Chen HS; Pellegrini JW; Aggarwal SK; Lei SZ; Warach S; Jensen FE; Lipton SA
    J Neurosci; 1992 Nov; 12(11):4427-36. PubMed ID: 1432103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathologically activated neuroprotection via uncompetitive blockade of N-methyl-D-aspartate receptors with fast off-rate by novel multifunctional dimer bis(propyl)-cognitin.
    Luo J; Li W; Zhao Y; Fu H; Ma DL; Tang J; Li C; Peoples RW; Li F; Wang Q; Huang P; Xia J; Pang Y; Han Y
    J Biol Chem; 2010 Jun; 285(26):19947-58. PubMed ID: 20404346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-activity analysis of binding kinetics for NMDA receptor competitive antagonists: the influence of conformational restriction.
    Benveniste M; Mayer ML
    Br J Pharmacol; 1991 Sep; 104(1):207-21. PubMed ID: 1686203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study.
    Kornhuber J; Bormann J; Hübers M; Rusche K; Riederer P
    Eur J Pharmacol; 1991 Apr; 206(4):297-300. PubMed ID: 1717296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-convulsant and adverse effects of the glycineB receptor ligands, D-cycloserine and L-701,324: comparison with competitive and non-competitive N-methyl-D-aspartate receptor antagonists.
    Wlaź P
    Brain Res Bull; 1998 Aug; 46(6):535-40. PubMed ID: 9744291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A comparative study of the central H-cholinergic-blocking and NMDA-blocking actions of MK-801, memantin, amantadine, pyrilen and IEM-1754 in experiments on intact rats].
    Gmiro VE; Serdiuk SE
    Eksp Klin Farmakol; 2000; 63(2):16-20. PubMed ID: 10834088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adaptations of NMDA and dopamine D2, but not of muscarinic receptors following 14 days administration of uncompetitive NMDA receptor antagonists.
    Hesselink MB; De Boer AG; Breimer DD; Danysz W
    J Neural Transm (Vienna); 1999; 106(5-6):409-21. PubMed ID: 10443547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents--preclinical studies.
    Danysz W; Parsons CG; Kornhuber J; Schmidt WJ; Quack G
    Neurosci Biobehav Rev; 1997 Jul; 21(4):455-68. PubMed ID: 9195603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis.
    Wenk GL; Danysz W; Mobley SL
    Eur J Pharmacol; 1995 Oct; 293(3):267-70. PubMed ID: 8666045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modifications of the behavioral profile of non-competitive NMDA receptor antagonists, memantine, amantadine and (+)MK-801 after chronic administration.
    Hesselink MB; Smolders H; De Boer AG; Breimer DD; Danysz W
    Behav Pharmacol; 1999 Feb; 10(1):85-98. PubMed ID: 10780305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor.
    Tricklebank MD; Singh L; Oles RJ; Preston C; Iversen SD
    Eur J Pharmacol; 1989 Aug; 167(1):127-35. PubMed ID: 2550253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of glutamate receptor antagonists on N-methyl-D-aspartate- and (S)-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-induced convulsant effects in mice and rats.
    Bisaga A; Krzascik P; Jankowska E; Palejko W; Kostowski W; Danysz W
    Eur J Pharmacol; 1993 Oct; 242(3):213-20. PubMed ID: 7506658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical evaluation of CHF3381 as a novel antiepileptic agent.
    Villetti G; Bregola G; Bassani F; Bergamaschi M; Rondelli I; Pietra C; Simonato M
    Neuropharmacology; 2001 Jun; 40(7):866-78. PubMed ID: 11378157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Memantine as an example of a fast, voltage-dependent, open channel N-methyl-D-aspartate receptor blocker.
    Parsons CG; Gilling K
    Methods Mol Biol; 2007; 403():15-36. PubMed ID: 18827985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of [3H]MK-801 binding to N-methyl-D-aspartate receptors in cultured rat cerebellar granule neurons and involvement in glutamate-mediated toxicity.
    Berman FW; Murray TF
    J Biochem Toxicol; 1996; 11(5):217-26. PubMed ID: 9110243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new pyrrolyl-quinoxalinedione series of non-NMDA glutamate receptor antagonists: pharmacological characterization and comparison with NBQX and valproate in the kindling model of epilepsy.
    Löscher W; Lehmann H; Behl B; Seemann D; Teschendorf HJ; Hofmann HP; Lubisch W; Höger T; Lemaire HG; Gross G
    Eur J Neurosci; 1999 Jan; 11(1):250-62. PubMed ID: 9987029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential effects of NMDA-receptor antagonists on long-term potentiation and hypoxic/hypoglycaemic excitotoxicity in hippocampal slices.
    Frankiewicz T; Pilc A; Parsons CG
    Neuropharmacology; 2000 Feb; 39(4):631-42. PubMed ID: 10728884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity.
    Volbracht C; van Beek J; Zhu C; Blomgren K; Leist M
    Eur J Neurosci; 2006 May; 23(10):2611-22. PubMed ID: 16817864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.